Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 129 clinical trials
Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]

The purpose of this study is to find out the effectiveness of pembrolizumab in combination with BCG as a first line therapy for participants with high grade T1 bladder cancer who are at "high risk" for BCG alone to be ineffective and are seeking an alternative treatment option to radical …

lymphadenectomy
carcinoma
neutrophil count
bladder tumor
intravesical bcg
  • 19 views
  • 04 Oct, 2022
  • 7 locations
Phase II Single Center Open-Label Single-Arm Study of the Safety and Efficacy of Oncolytic Adenovirus H101 Combined With PD-1 Inhibitor in Patients With Non-muscle-invasive Bladder Cancer Who Failed BCG Therapy

objective of this phase II clinical trial is to investigate the safety and efficacy of H101 combined with PD-1 inhibitor Camrelizumab in patients with non-muscle-invasive bladder cancer who failed BCG

neutrophil count
bladder tumor
invasive bladder cancer
carcinoma
  • 0 views
  • 20 Oct, 2022
  • 1 location
The Effectiveness and Safety of Neoadjuvant Intravesical Mitomycin-C Instillation

The aim of this study is to evaluate the effectiveness and safety of neoadjuvant intravesical mitomycin-C instillation in non-muscle invasive bladder cancer patients

mitomycin
cancer
bladder tumor
transurethral resection
invasive bladder cancer
  • 12 views
  • 23 Apr, 2022
  • 1 location
Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncer

Open, multicentre, phase II trial of atezolizumab with concurrent normofractionated radiotherapy in patients with localized muscle-invasive bladder cancer treated with a selective multimodality

carcinoma
neutrophil count
bladder tumor
atezolizumab
aptt
  • 41 views
  • 20 Feb, 2022
  • 10 locations
Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBC

bladder cancer (NMIBC).

intravesical administration
carcinoma
bladder tumor
neutrophil count
invasive bladder cancer
  • 1 views
  • 19 Apr, 2022
  • 1 location
A Phase I Single-Arm Study of the Combination of Durvalumab (MEDI4736) and Vicineum (Oportuzumab Monatox, VB4-845) in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Gu(SqrRoot)(Copyright)Rin (BCG)

Background Non-muscle-invasive bladder cancer is in the early stages. But it usually comes back after treatment. The drugs Vicineum and Durvalumab may help the

transitional cell carcinoma
bcg vaccine
carcinoma
neutrophil count
bladder tumor
  • 257 views
  • 23 Oct, 2022
  • 1 location
Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy (BladderSpar)

Patients older than ≥18 years, with muscle-invasive bladder cancer unfit for radical cystectomy because of age, comorbidities, and/or patient's refusal. This study is designed as a

bladder tumor
atezolizumab
transurethral bladder excision
invasive bladder cancer
bladder cancer
  • 0 views
  • 04 Oct, 2022
  • 12 locations
Comparison of the Efficacy and Safety of Continuous and Single-Dose Intravesical Epirubicin Instillation

in low and intermediate risk non-muscle-invasive bladder cancer.

transurethral resection
transurethral bladder excision
invasive bladder cancer
bladder tumor
  • 0 views
  • 04 Oct, 2022
  • 1 location
Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment

high-risk non-muscle-invasive bladder cancer who failed BCG therapy.

radical cystectomy
carcinoma
neutrophil count
bladder tumor
bladder instillation
  • 0 views
  • 18 Oct, 2021
  • 3 locations
Effectiveness of an Immediate Postoperative Intravesical Instillation With Either Gemcitabine or Epirubicin in Patients With Urinary Bladder Cancer (Gemcitabine Epirubicin Normal SAline) (GENSA)

The natural history of non-muscle-invasive bladder cancer is characterised by recurrence and progression. We compare the effectiveness of gemcitabine hydrochloride and epirubicin hydrochloride

gemcitabine
transurethral resection
invasive bladder cancer
bladder tumor
  • 0 views
  • 22 Mar, 2022
  • 1 location